Project description
Relief from chronic pain due to secondary bone cancer may be on the horizon
The skeleton is most often affected by metastatic cancer. In fact, secondary bone cancers are more common than primary bone cancers. Significant pain, often characterised by back ache, has been challenging to treat effectively, leading to impaired mobility and reduced quality of life. APAC is preparing clinical validation and a business plan to commercialise their innovative Dynamic-ElectroEnhanced Pain Control (D-EEPC) treatment to reduce tumours and pain associated with secondary bone cancer. Electroporation, the application of short, high-voltage electrical pulses to enhance cells' permeability, will permit the targeted delivery of anti-cancer drugs. Patients will get substantial relief from the chronic pain associated with secondary bone cancers.
Objective
This Phase 1 project will enable Scandinavian ChemoTech AB (ChemoTech) to develop a business plan for Dynamic-ElectroEnhanced Pain Control (D-EEPC). This will include clinical and market feasibility, with a strong business development and commercialisation strategy.
Approximately 25% of all cancer patients are affected by secondary bone cancer; which is difficult to find and treat. 20-30% of these patients do not respond to current systemic therapies and pain control with narcotic analgesics, radiation therapy and surgery. This patient population continues to experience potentially debilitating back pain.
To address this, ChemoTech has developed D-EEPC - a game-changing pain reduction treatment for secondary bone cancer. It operates by sending short, high voltage electric pulses in combination with a low concentration of a cytostatic drug to reduce tumour size in the spine or bones. This reduces pain caused by pressure on nerves. The different voltage settings and use of an applicator with different sizes allows treatment of hard-to-treat cancers and distinguishes D-EEPC from its competitors.
Development of D-EEPC and research supporting its efficacy and safety to date is extremely promising but requires full clinical validation and an optimal business strategy. The proposed Phase 1 project will enable the company to define the pathway to implement for successful commercialisation.
Fields of science
Programme(s)
Funding Scheme
SME-1 - SME instrument phase 1Coordinator
223 81 MALMO
Sweden
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.